Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.55 |
| ▸ | EDNRB | P24530 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20831831 | 0.94 | ESR1 (0.58) | ESR1ESR2EDNRBEDNRAALDH1A1 | |
| SCHEMBL30362855 | 0.94 | ESR1 (0.58) | ESR1ESR2EDNRBEDNRAALDH1A1 | |
| SCHEMBL2604720 | 0.94 | ESR1 (0.58) | ESR1ESR2EDNRBEDNRAALDH1A1 | |
| SCHEMBL15312307 | 0.94 | ESR1 (0.58) | ESR1ESR2EDNRBEDNRAALDH1A1 | |
| SCHEMBL20831829 | 0.94 | ESR1 (0.58) | ESR1ESR2EDNRBEDNRAALDH1A1 | |
| SCHEMBL15013033 | 0.94 | ESR1 (0.58) | ESR1ESR2EDNRBEDNRAALDH1A1 | |
| SCHEMBL239999 | 0.94 | ESR1 (0.58) | ESR1ESR2EDNRBEDNRAALDH1A1 | |
| SCHEMBL19771459 | 0.93 | ESR1 (0.50) | ESR1ESR2EDNRBEDNRAALDH1A1 | |
| SCHEMBL24103714 | 0.91 | ESR2 (0.52) | ESR1ESR2ALDH1A1MAPTMEN1 | |
| SCHEMBL15006416 | 0.91 | ESR2 (0.52) | ESR1ESR2ALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20100130598-A1 | METHODS FOR INDUCING PROGRAMMED CELL DEATH | NOVOGEN RESEARCH PTY LTD. (AU) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | ESR1 1328/4885ESR2 1134/4885EDNRB 4265/4885 |
| US-20100130598-A1 | METHODS FOR INDUCING PROGRAMMED CELL DEATH | CASP3, BAX, BAD | ESR1 4604/4885ESR2 3077/4885EDNRB 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.